Policy | November 08, 2023
Indian pharmaceutical companies have become reliable and affordable suppliers of high-quality drugs: MoS Bhagwant Khuba
Lack of technology transfer stands out as a formidable barrier
Lack of technology transfer stands out as a formidable barrier
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
Prior to this, Jim held leadership positions at several companies, including Centrient Pharmaceuticals, Leo Pharmaceuticals, Sandoz, Xellia, and GSK
Subscribe To Our Newsletter & Stay Updated
